Submission
| Title: | Clomiphene Citrate Therapy Effects on Lipid Panels in Men with Hypogonadism |
| Presenter: | Ahsan Siddiqui |
| Institution: | Indiana University School of Medicine |
| Authors: | Ahsan, Siddiqui, Indiana University School of Medicine; Thairo, Pereira MD, Indiana University Department of Urology; Helen, Bernie DO MPH, Indiana University Department of Urology |
Abstract
| Background/Significance/Rationale: | Clomiphene citrate (CC) is a selective estrogen receptor modulator FDA approved for women with ovulatory dysfunction, yet used to improve testosterone production in men with hypogonadism. CC is contraindicated in patients with high triglyceride (TG) lab values, but little data exists evaluating the impact of CC on lipid panels in men with hypogonadism treated with CC. This study aims to provide information on the effects of CC on TG lab values. |
| Methods: | We conducted a retrospective chart review on hypogonadism patients from January 2020 – August 2024. Pre-treatment endocrine and lipid profiles collected before 11am fasting were compared to panels collected 4 weeks after beginning treatment. A paired t-test was performed to determine statistically significant differences in lipid profiles before and after CC therapy. |
| Results/Findings: | 52 men with a mean age of 42.4 had complete data and were included in this study. Mean testosterone levels were 322 ng/dl pre-CC and 502 ng/dl post-CC treatment. Pre-CC Triglyceride (TG), Total Cholesterol (TC), HDL, and LDL means were 141.9, 172.4, 43.3, and 100.9, respectively. Post-CC TG, TC, HDL, and LDL means were 140.9, 171.5, 40.1, and 103.2, respectively. We found no statistically significant difference in the change of triglyceride (p = 0.903, SD = 39.3), total cholesterol (p = 0.783, SD = 14.01), and low-density lipoprotein (p = 0.447, SD = 24.3) lab values before and after treatment with CC. We observed a statistically significant decrease in high-density lipoprotein lab values (p < 0.001, SD = 12.95). |
| Conclusions/Discussion: | CC therapy for male hypogonadism decreases HDL levels. CC does not seem to significantly affect other parameters in the lipid profile of patients. |
| Translational/Human Health Impact: | Lipid profiles of patients on CC therapy should be monitored, especially if there are risk factors such as cardiovascular disease, obesity, HTN, old age etc. |
